NasdaqGM:RNABiotechs
Did Avidity's (RNA) $620 Million Lonza Deal and Steep Q2 Loss Just Shift Its Investment Narrative?
Avidity Biosciences recently reported its second quarter 2025 earnings, revealing a net loss of US$157.32 million and basic loss per share from continuing operations of US$1.21, both higher than for the same period last year.
Avidity also entered into a multi-year manufacturing agreement with Lonza, committing to purchase approximately US$620 million in drug products between 2026 and 2028 to support future commercial plans.
We'll explore how Avidity's major manufacturing commitment with...